EP4743107A1 - TREATMENT OF HYPERPIGMENTATION CONDITIONS WITH BOTULINUM TOXIN - Google Patents

TREATMENT OF HYPERPIGMENTATION CONDITIONS WITH BOTULINUM TOXIN

Info

Publication number
EP4743107A1
EP4743107A1 EP24743360.0A EP24743360A EP4743107A1 EP 4743107 A1 EP4743107 A1 EP 4743107A1 EP 24743360 A EP24743360 A EP 24743360A EP 4743107 A1 EP4743107 A1 EP 4743107A1
Authority
EP
European Patent Office
Prior art keywords
treatment
botulinum toxin
hyperpigmentation conditions
hyperpigmentation
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24743360.0A
Other languages
German (de)
French (fr)
Inventor
Kay Marquardt
Thomas Hengl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Publication of EP4743107A1 publication Critical patent/EP4743107A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
EP24743360.0A 2023-07-12 2024-07-11 TREATMENT OF HYPERPIGMENTATION CONDITIONS WITH BOTULINUM TOXIN Pending EP4743107A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23185114 2023-07-12
PCT/EP2024/069733 WO2025012403A1 (en) 2023-07-12 2024-07-11 Treatment of hyperpigmentation conditions by botulinum toxin

Publications (1)

Publication Number Publication Date
EP4743107A1 true EP4743107A1 (en) 2026-05-20

Family

ID=87280519

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24743360.0A Pending EP4743107A1 (en) 2023-07-12 2024-07-11 TREATMENT OF HYPERPIGMENTATION CONDITIONS WITH BOTULINUM TOXIN

Country Status (7)

Country Link
EP (1) EP4743107A1 (en)
KR (1) KR20260035809A (en)
CN (1) CN121511091A (en)
AU (1) AU2024288687A1 (en)
IL (1) IL324338A (en)
MX (1) MX2025013627A (en)
WO (1) WO2025012403A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (en) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutic with a botulinum neurotoxin
DE10333317A1 (en) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulation for protein medicines without the addition of human serum albumin (HSA)
KR100852824B1 (en) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 Therapeutic composition comprising botulinum neurotoxin
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
KR101640694B1 (en) 2011-09-29 2016-07-18 셀스냅, 엘엘씨 Compositions and methods for toxigenicity testing
JP6608357B2 (en) 2013-06-28 2019-11-20 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー Means and methods for determining biological activity of neurotoxin polypeptides in cells
WO2018222652A1 (en) 2017-05-31 2018-12-06 Allergan, Inc. Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin

Also Published As

Publication number Publication date
AU2024288687A1 (en) 2025-10-23
IL324338A (en) 2025-12-01
CN121511091A (en) 2026-02-10
WO2025012403A1 (en) 2025-01-16
KR20260035809A (en) 2026-03-13
MX2025013627A (en) 2025-12-01

Similar Documents

Publication Publication Date Title
EP4041212C0 (en) MEK INHIBITORS FOR THE TREATMENT OF HANTAVIRUS INFECTIONS
EP3773880C0 (en) THERAPEUTIC MODULATION TO TREAT BLOOD GLUCOSE ABNORMALITY, INCLUDING TYPE 2 DIABETES, AND/OR TO REDUCE HBA1C LEVELS
DK4087641T3 (en) BLOOD PUMP WITH IMPROVED LEAKAGE CONTROL AND METHOD FOR MANUFACTURING THEREOF
IL304733A (en) Improved use of botulinum toxin to treat sialorrhea
EP3537982A4 (en) CONTROLLED TREATMENT OF TISSUE AND DYNAMIC INTERACTION WITH AND COMPARISON OF TISSUE AND / OR TREATMENT DATA
EP4493175A4 (en) MIRDAMETINIB TREATMENT
EP4216952A4 (en) TREATMENT OF COGNITIVE DISORDERS WITH PYRROLOPYRIDINANILINE COMPOUNDS
EP4352231A4 (en) TREATMENT OF ANGPTL4-RELATED DISEASES
EP3784280A4 (en) TREATMENT OF ATOPIC DERMATITIS
EP4222265A4 (en) TREATMENT OF OPTICAL ATROPHY
EP3900728A4 (en) URSODEOXYCHOLIC AGENT USED TO TREAT OR PREVENT PRESBYOPIA
CO2019014592A2 (en) Botulinum neurotoxin for the treatment of disorders associated with melanocyte hyperactivity and / or excess melanin
EP4413032A4 (en) TREATMENT OF MASTCELL-INDUCED DISEASES
AR119101A1 (en) TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES
IL285634A (en) New uses of the botulinum neurotoxin to treat tremors
EP4238567A4 (en) NOVEL TREATMENT AND PREVENTION OF SARCOPENIA-RELATED DISEASES
EP4508207A4 (en) TREATMENT OF ARGINASE-1 DEFICIENCY
EP4240354A4 (en) RAF INHIBITORS FOR THE TREATMENT OF LOW-GRADE GLIOMAS
EP4121169A4 (en) INJECTABLE BOTULINUM TOXIN PROCEDURES FOR THE TREATMENT OF HEADACHES
EP4041275B1 (en) TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY DAMAGE
EP4502155A4 (en) Microbial carrier and water treatment process
EP4126079C0 (en) TREATMENT OF URINARY CATHETERS
EP4081242C0 (en) TREATMENT OF ACUTE HEART FAILURE
EP4157332A4 (en) METHODS OF TREATING VIRUS INFECTIONS WITH PROTEASE INHIBITORS
EP4507689A4 (en) TREATMENT OF SEIZURES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE